Liam Mannion

Liam Mannion

Auto-generated profile, based on publicly available information

Liam Mannion

City University of London London UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2020 in BJU International
Verified
Journal Article
Closed access
PDF file
LMLiam Mannion
Liam Mannion
CBCecilia Bosco
Cecilia Bosco
RNRajesh Nair
Rajesh Nair
VMVinod Mullassery
Vinod Mullassery
DEDeborah Enting
Deborah Enting
SHSimon Hughes
Simon Hughes

11 October 2024 in BJUI Compass
Verified
Journal Article
Open access
LMLiam Mannion
Liam Mannion
VWVerity Watson
Verity Watson
VMVinod Mullassery
Vinod Mullassery
RNRajesh Nair
Rajesh Nair
TCThomas Charlton
Thomas Charlton
SHSimon Hughes
Simon Hughes
Background: When faced with treatment options, patients are asked to participate in decision‐making. We sought to determine which treatment aspects matter most for individuals treated for muscle invasive bladder cancer (MIBC), with an aim to improve understanding of patient preferences and what trade‐offs patients are willing to accept. Our study consisted of a discrete choice experiment (DCE): a type of questionnaire used to elicit preferences in the absence of real‐world choice.Methods: The DCE had five attributives, each with three levels. Participants were asked to complete a questionnaire in which they were asked to choose between two hypothetical MIBC treatments. The data were analysed using a conditional logit model, and preferences for, and trade‐offs between, attributes were estimated.Results: We recruited patients with MIBC who had either already completed, were undergoing or had yet to commence radical treatment for MIBC (n = 60). Participants indicated a strong preference for treatments that increased their life expectancy (p = <0.001), had a lower risk of long‐term complications (p = <0.001) and less changes to their body image (p = <0.001). Changes to sexual wellbeing (p = 0.09) or an increase in acute side effects (p = 0.99) did not influence preferences. Patients were willing to accept treatments with higher risk of long‐term complications to improve their life expectancy or body image.Conclusion: When deciding on the type of treatment, increased life expectancy is the most important consideration for people with MIBC. The risk of long‐term complications and changes to overall body image as a result of treatment are also important. Our study also highlighted that patients are willing to accept a higher risk of long‐term complications to improve other treatment outcomes. Understanding patient preferences is important for shared decision‐making, which has an impact on quality of care for people living with MIBC.

12 November 2022 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
JRJohn T Ryan
John T Ryan
MNMasao NAKAYAMA
Masao NAKAYAMA
IGIan Gleeson
Ian Gleeson
LMLiam Mannion
Liam Mannion
MGMoshi Geso
Moshi Geso
NHNicholas Hardcastle
Nicholas Hardcastle
Rationale: This systematic review aims to synthesise the outcomes of different strategies of incorporating functional biological markers in the radiation therapy plans of patients with glioblastoma to support clinicians and further research.Methods: The systematic review protocol was registered on PROSPERO (CRD42021221021). A structured search for publications was performed following PRISMA guidelines. Quality assessment was performed using the Newcastle–Ottawa Scale. Study characteristics, intervention methodology and outcomes were extracted using Covidence. Data analysis focused on radiation therapy target volumes, toxicity, dose distributions, recurrence and survival mapped to functional image-guided radiotherapy interventions.Results: There were 5733 citations screened, with 53 citations (n = 32 studies) meeting review criteria. Studies compared standard radiation therapy planning volumes with functional image-derived volumes (n = 20 studies), treated radiation therapy volumes with recurrences (n = 15 studies), the impact on current standard target delineations (n = 9 studies), treated functional volumes and survival (n = 8 studies), functionally guided dose escalation (n = 8 studies), radiomics (n = 4 studies) and optimal organ at risk sparing (n = 3 studies). The approaches to target outlining and dose escalation were heterogeneous. The analysis indicated an improvement in median overall survival of over two months compared with a historical control group. Simultaneous-integrated-boost dose escalation of 72–76 Gy in 30 fractions appeared to have an acceptable toxicity profile when delivered with inverse planning to a volume smaller than 100 cm $$^3$$3 .Conclusion: There was significant heterogeneity between the approaches taken by different study groups when implementing functional image-guided radiotherapy. It is recommended that functional imaging data be incorporated into the gross tumour volume with appropriate technology-specific margins used to create the clinical target volume when designing radiation therapy plans for patients with glioblastoma.

19 September 2022 in Journal of Medical Imaging and Radiation Sciences
Verified
Journal Article
Closed access
NSNikolaos Stogiannos
Nikolaos Stogiannos
ESEmily Skelton
Emily Skelton
CRCharlie Rogers
Charlie Rogers
MSMeera Sharma
Meera Sharma
SPStamatia Papathanasiou
Stamatia Papathanasiou
CMChristina Malamateniou
Christina Malamateniou

1 January 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
LMLiam Mannion
Liam Mannion
MHMieke Van Hemelrijck
Mieke Van Hemelrijck
SHSimon Hughes
Simon Hughes
Purpose: Muscle-invasive bladder cancer (MIBC) is an aggressive disease with a high mortality rate. Treatment typically involves a cystectomy which is an undesirable option for most patients. Objectives: To evaluate the clinical effectiveness of brachytherapy for solitary urinary bladder tumours in terms of survival. Methods: A systematic review was conducted using the preferred reporting items of systematic reviews and meta-analysis (PRISMA) guidelines with defined search terms: an online search was performed using the PubMed database with the terms brachytherapy AND urinary bladder cancer AND survival. Three individual searches were performed using MeSH and title/abstract searches. The builder option was used to combine the three initial searches which resulted in 80 articles. Results: 21 studies were included in the final analysis. Ten separate endpoints were reported within the articles, 17 of the 21 articles reported overall survival at 5 years, with a combined number of 2889 patients at risk and 1775 alive after 5 years (61.4%) Conclusion: Brachytherapy for MIBC is an alternative (and organ preserving option) for solidarity (<5cm) tumours when combined with a short course of external beam radiotherapy.